Browse PDCD6IP

Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol Melanosome Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Secreted, exosome Cell junction, tight junction Midbody, Midbody ring Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Colocalized with CEP55 at centrosomes of non-dividing cells. Component of the actomyosin-tight junction complex (By similarity). PDCD6IP targeting to the midbody requires the interaction with CEP55 (PubMed:18641129).
Domain PF13949 ALIX V-shaped domain binding to HIV
PF03097 BRO1-like domain
Function

Multifunctional protein involved in endocytosis, multivesicular body biogenesis, membrane repair, cytokinesis, apoptosis and maintenance of tight junction integrity. Class E VPS protein involved in concentration and sorting of cargo proteins of the multivesicular body (MVB) for incorporation into intralumenal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome. Binds to the phospholipid lysobisphosphatidic acid (LBPA) which is abundant in MVBs internal membranes. The MVB pathway requires the sequential function of ESCRT-O, -I,-II and -III complexes (PubMed:14739459). The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis (PubMed:17853893, PubMed:17556548). Adapter for a subset of ESCRT-III proteins, such as CHMP4, to function at distinct membranes. Required for completion of cytokinesis (PubMed:17853893, PubMed:17556548, PubMed:18641129). May play a role in the regulation of both apoptosis and cell proliferation. Regulates exosome biogenesis in concert with SDC1/4 and SDCBP (PubMed:22660413). By interacting with F-actin, PARD3 and TJP1 secures the proper assembly and positioning of actomyosin-tight junction complex at the apical sides of adjacent epithelial cells that defines a spatial membrane domain essential for the maintenance of epithelial cell polarity and barrier (By similarity). ; FUNCTION: (Microbial infection) Involved in HIV-1 virus budding. Can replace TSG101 it its role of supporting HIV-1 release; this function requires the interaction with CHMP4B. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as enveloped virus budding (HIV-1 and other lentiviruses).

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0000920 cell separation after cytokinesis
GO:0006887 exocytosis
GO:0006900 membrane budding
GO:0007032 endosome organization
GO:0007033 vacuole organization
GO:0007098 centrosome cycle
GO:0010824 regulation of centrosome duplication
GO:0016050 vesicle organization
GO:0017157 regulation of exocytosis
GO:0019058 viral life cycle
GO:0019068 virion assembly
GO:0031023 microtubule organizing center organization
GO:0032886 regulation of microtubule-based process
GO:0036257 multivesicular body organization
GO:0036258 multivesicular body assembly
GO:0039702 viral budding via host ESCRT complex
GO:0044089 positive regulation of cellular component biogenesis
GO:0044803 multi-organism membrane organization
GO:0045921 positive regulation of exocytosis
GO:0046605 regulation of centrosome cycle
GO:0046755 viral budding
GO:0051047 positive regulation of secretion
GO:0051297 centrosome organization
GO:0051298 centrosome duplication
GO:0051493 regulation of cytoskeleton organization
GO:0060627 regulation of vesicle-mediated transport
GO:0070507 regulation of microtubule cytoskeleton organization
GO:0071971 extracellular exosome assembly
GO:0090611 ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway
GO:1902115 regulation of organelle assembly
GO:1902117 positive regulation of organelle assembly
GO:1902590 multi-organism organelle organization
GO:1902592 multi-organism membrane budding
GO:1903532 positive regulation of secretion by cell
GO:1903541 regulation of exosomal secretion
GO:1903543 positive regulation of exosomal secretion
GO:1903551 regulation of extracellular exosome assembly
GO:1903553 positive regulation of extracellular exosome assembly
GO:1990182 exosomal secretion
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0031871 proteinase activated receptor binding
GO:0048306 calcium-dependent protein binding
Cellular Component GO:0001772 immunological synapse
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0042470 melanosome
GO:0043209 myelin sheath
GO:0048770 pigment granule
GO:0070971 endoplasmic reticulum exit site
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-162588: Budding and maturation of HIV virion
R-HSA-1643685: Disease
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-5339562: Uptake and actions of bacterial toxins
R-HSA-5210891: Uptake and function of anthrax toxins
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PDCD6IP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PDCD6IP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PDCD6IP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1270.629
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2830.899
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0170.992
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0120.969
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1950.931
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2780.925
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1470.745
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0330.987
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3480.881
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.480.762
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.190.61
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.080.197
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PDCD6IP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PDCD6IP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PDCD6IP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PDCD6IP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PDCD6IP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PDCD6IP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PDCD6IP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPDCD6IP
Nameprogrammed cell death 6 interacting protein
Aliases Alix; Hp95; ALG-2 interacting protein X; programmed cell death 6-interacting protein; DRIP4; ALG-2 interacti ......
Chromosomal Location3p22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PDCD6IP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.